Arcellx(us:ACLX)

    75.51

    -0.04%

    Updated on 2024-12-23

    Open:75.13
    Close:75.51
    High:76.28
    Low:74.11
    Pre Close:75.54
    Volume:147243.00
    Amount:11.10M
    Turnover:0.27%
    Shares:54.07M
    MarketCap:4.08B
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-306205750.04%022
    2024-03-311894696525088.14%386968
    2023-12-311734673529189.39%366065
    2023-09-301514755525297.70%175856
    2023-06-301474816437599.69%326642
    2023-03-311364547500095.05%154662
    2022-12-311274187462194.94%543532
    2022-09-30864165203895.00%183528
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Fmr Llc539449510.12%101532623.18%
    2024-03-31Perceptive Advisors Llc39335567.38%-611253-13.45%
    2024-03-31Paradigm Biocapital Advisors Lp38180957.17%1594714.36%
    2024-03-31Nea Management Company, Llc37452627.03%0
    2024-03-31Blackrock Inc.30660685.75%475301.57%
    2024-03-31Sr One Capital Management, Lp23466304.40%-800000-25.42%
    2024-03-31Vanguard Group Inc22288564.18%1670378.10%
    2024-03-31State Street Corp18851183.54%1112796.27%
    2024-03-31Cormorant Asset Management, Lp17800003.34%800004.71%
    2024-03-31Suvretta Capital Management, Llc15623542.93%-873620-35.86%

    About

    Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
    Address:25 West Watkins Mill Road,Suite A

    Market Movers